The primary failed. The key secondary failed. But this biotech still believes it can win an FDA OK in ALS
Two years after the executive team at BrainStorm Cell Therapeutics decided to back off a controversial attempt to sell their stem cell therapy for ALS under the new ‘Right to Try’ legislation, the biotech is back with the top-line data from Phase III. And the data aren’t good.
Researchers say the drug — with a once-proposed price of $300,000 — failed the primary endpoint as well as the key secondaries on disease progression. But the executive crew still thinks it’s approvable. And in fact, the biotech also insists the FDA is eager to review it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.